Mithra Pharmaceuticals S.A.

MITRA

BE0974283153

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 11:35:26 2024-04-26 am EDT			5-day change	1st Jan Change
0.216 ^EUR	-1.82%		-3.57%	-82.78%

Apr. 22	Mithra Pharmaceuticals Obtains Court Protection Measures	MT
Mar. 08	Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023

March 08, 2024 at 01:00 am EST

Mithra Pharmaceuticals SA reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 40.16 million compared to EUR 67 million a year ago. Net loss was EUR 173.5 million compared to EUR 59.62 million a year ago.

Latest news about Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals Obtains Court Protection Measures	Apr. 22	MT
Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Mithra Pharmaceuticals to Initiate Monetization Process Involving Sale of Assets, Business	Mar. 05	MT
Mithra Pharmaceuticals Terminates CEO; Names CFO, COO as Successors	Mar. 05	MT
Mithra Pharmaceuticals SA Announces CEO Changes	Mar. 05	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Mithra: share price falls, financial visibility reduced	Feb. 06	CF
Mithra : Goldman Sachs reduces its stake to below 3%.	Dec. 27	CF
Mithra Pharmaceuticals Completes Pediatric Study of Contraceptive Product in Adolescent Women	Dec. 21	MT
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China	Dec. 04	MT
Mithra Pharmaceuticals SA and Gedeon Richter Plc. Signs Binding Head of Terms to Commercialize Estelle and Donesta in China	Dec. 04	CI
Mithra Pharmaceuticals to Conduct Additional Data Analysis for Menopause-candidate Drug	Nov. 30	MT
Certain Ordinary Shares of Mithra Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-NOV-2023.	Nov. 25	CI
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mithra and Searchlight Pharma Sign DONESTA Licensing Agreement for Canada	23-10-26	CI
Mithra Pharmaceuticals Signs License Agreement for Menopause Drug With Canada's Searchlight Pharma	23-10-26	MT
Mithra and Searchlight Pharma Inc. Signs License and Supply Agreement for the Canadian Rights to DONESTA	23-10-26	CI
Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	23-10-23	MT
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023	23-09-27	CI
Mithra Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Mithra Pharmaceuticals SA(ENXTBR:MITRA) dropped from S&P Global BMI Index	23-09-18	CI
Mithra Pharmaceuticals Raises EUR20 Million in Private Placement	23-08-29	MT
Mithra Pharmaceuticals SA announced that it has received ?20 million in funding from Armistice Capital, LLC	23-08-27	CI

Chart Mithra Pharmaceuticals S.A.

Duration

Period

More charts

Company Profile

Mithra Pharmaceuticals S.A. is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, the Company is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Mithra Pharmaceuticals S.A.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.216 EUR

Average target price

0.11 EUR

Spread / Average Target

-49.07%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MITHRA PHARMACEUTICALS S.A.	-82.78%	15.94M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals